Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Connor

Showing results (591-600 of 804) with videos related to

Pageof 81
Sort By:
The Journal of Infection|December 3, 2025
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trialE Kelly, M Greenland, P de Whalley, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma SubtypesBimarzhan Assatova, Robert Willim, Christopher Trevisani, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Bone Marrow Transplantation|August 23, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemiaTimothy E O'Connor, Chenyu Lin, Gregory W Roloff, et al.
Blood|February 5, 2026
Blinatumomab Nonresponse Correlates with Poor Survival After BrexucabtageneHrishikesh Krishna Srinagesh, Vishal K Gupta, Amy Zhang, et al.
The European Physical Journal. C, Particles and Fields|June 1, 2019
Measurement of the <math></math> production cross section, the top quark mass, and the strong coupling constant using dilepton events in pp collisions at <math> </math>A M Sirunyan, A Tumasyan, W Adam, et al.
Physical Review Letters|December 30, 2017
Observation of Top Quark Production in Proton-Nucleus CollisionsA M Sirunyan, A Tumasyan, W Adam, et al.
Pageof 81

Showing results (591-600 of 804) with videos related to

Sort By:
Pageof 81
The Journal of Infection|December 3, 2025
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trialE Kelly, M Greenland, P de Whalley, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma SubtypesBimarzhan Assatova, Robert Willim, Christopher Trevisani, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Bone Marrow Transplantation|August 23, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemiaTimothy E O'Connor, Chenyu Lin, Gregory W Roloff, et al.
Blood|February 5, 2026
Blinatumomab Nonresponse Correlates with Poor Survival After BrexucabtageneHrishikesh Krishna Srinagesh, Vishal K Gupta, Amy Zhang, et al.
The European Physical Journal. C, Particles and Fields|June 1, 2019
Measurement of the <math></math> production cross section, the top quark mass, and the strong coupling constant using dilepton events in pp collisions at <math> </math>A M Sirunyan, A Tumasyan, W Adam, et al.
Physical Review Letters|December 30, 2017
Observation of Top Quark Production in Proton-Nucleus CollisionsA M Sirunyan, A Tumasyan, W Adam, et al.
Pageof 81